ClinicalTrials.gg
Not yet recruitingNCT07781007Updated Oct 2, 2026

Effectiveness of a Board Game Intervention on Cognitive and Functional Outcomes in Older Adults With Schizophrenia

An interventional study of Scaffolding-Based Board Game Intervention in Schizophrenia, sponsored by Kaohsiung Kai-Suan Psychiatric Hospital. Not yet recruiting at 1 site in Taiwan. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Kaohsiung Kai-Suan Psychiatric Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Study summary

This study aims to evaluate the effects of a scaffolding-based board game intervention on cognitive and functional outcomes in older adults with schizophrenia living in psychiatric nursing homes. Participants will be assigned by clusters to either an intervention group or a control group. The intervention group will receive a 12-week board game training program, while the control group will receive usual care. Cognitive and functional outcomes will be assessed before the intervention, immediately after the 12-week intervention, and three months after the intervention. The study will examine whether the board game intervention can improve cognitive and daily functioning in older adults with schizophrenia.

02

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Older Adults
  • Board Game Intervention
  • Cognitive Function
  • Psychiatric Nursing Home
03

In context

Schizophrenia

3,563 studies on the registry are indexed under Schizophrenia; 491 are open to participants now.

This study's planned enrollment of 76 is close to the median of 71 across 2,944 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Kaohsiung Kai-Suan Psychiatric Hospital is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 55 years or older.
  2. Diagnosed with schizophrenia by a board-certified psychiatrist.
  3. Has completed at least elementary school education.
  4. Has basic verbal communication ability and is able to understand and cooperate with study assessments and activities.
  5. Has sufficient vision and hearing, as assessed by care staff, to participate in board game instructions and activities.
  6. Is willing to participate in the study and provides written .

Exclusion criteria

Exclusion Criteria:

  1. Has severe sensory impairment.
  2. Has severe visual or hearing impairment that interferes with participation in the study activities.
  3. Has experienced an acute exacerbation of psychiatric symptoms within the past 3 months.
  4. Is currently receiving other cognitive training or participating in another research study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Scaffolding-Based Board Game Intervention

    Behavioral: Scaffolding-Based Board Game Intervention

  • No intervention
    Control Group

Interventions

  • BehavioralScaffolding-Based Board Game Intervention

    Participants will receive a scaffolding-based board game intervention once weekly for 12 weeks, with each session lasting approximately 60 minutes.

06

What researchers measure

Primary outcomes

  1. Cognitive Function Assessed by MoCA-TW 7.1

    The Montreal Cognitive Assessment-Taiwan Version 7.1 (MoCA-TW 7.1) is used to assess global cognitive function. The total score ranges from 0 to 30, with higher scores indicating better cognitive function.

    Time frame: Baseline, immediately after the 12-week intervention, and 3 months after completion of the intervention

07

Study locations

1 site
  • Daliao Psychiatric Nursing Home, Kaohsiung Municipal Kai-Syuan Psychiatric Hospital
    Kaohsiung City, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 2 months later.

Of 753 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 2 months is below that.

Counting every sponsor, half of 766 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2026
First posted
Aug 24, 2026
StartEst.
Sep 9, 2026
Primary completionEst.
Dec 2, 2026
CompletionEst.
Mar 2, 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07781007
Lead sponsor
Kaohsiung Kai-Suan Psychiatric Hospital
Responsible party
Sponsor
First posted
Aug 24, 2026
Start date
Sep 9, 2026 (estimated)
Primary completion
Dec 2, 2026 (estimated)
Completion
Mar 2, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

CHIU JUNG CHANG
Contact
joce0989@gmail.com
+886-989-341-120

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion